JLJingpei Li

Jingpei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingpei Li has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Jianxing He

    Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

    5 shared publications
  • Fei Cui

    Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

    4 shared publications
  • Jun Liu

    Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    3 shared publications
  • Guilin Peng

    2 shared publications
  • Wei Wang

    Department of Thoracic Surgery The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

    2 shared publications
  • Weifeng Yue

    State Key Lab of Respiratory Diseases Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

    2 shared publications

Latest Publications

  • Open Access

    MUC1 and HIF-1α Signaling Crosstalk Regulates Endoplasmic Reticulum Stress and Mitochondrial Dysfunction to Accelerate Apoptosis and Necroptosis of Alveolar Type II Cells in Lung Fibrosis

    by Ruijuan Guan, Liang Yuan, Jingpei Li, See Pdf

    Endoplasmic reticulum (ER) stress and mitochondrial dysfunction drive alveolar type II (AT2) cell apoptosis and necroptosis, which are central to the pathogenesis of idiopathic pulmonary fibrosis (IPF). Although mucin 1 (MUC1) is known to exert anti-inflammatory effects in the airways, its direct role in AT2 cells during pulmonary fibrosis remains unclear. Here, we show that MUC1 expression was specifically and significantly upregulated in AT2 cells from IPF patients and bleomycin (BLM)-induced fibrotic mice, and this upregulation correlated with disease severity. AT2 cell specific Muc1 knockout attenuated BLM-induced pulmonary fibrosis, reduced AT2 cell apoptosis and necroptosis, and alleviated ER stress and mitochondrial dysfunction in vivo. Consistently, silencing MUC1 in human A549 AT2-like cells suppressed BLM-triggered ER stress, mitochondrial dysfunction, apoptosis, and necroptosis. Mechanistically, hypoxia-inducible factor (HIF)-1α was identified as a major MUC1-interacting partner, with its protein levels significantly decreased upon MUC1 inhibition in both in vivo and in vitro models of pulmonary fibrosis. Co-immunoprecipitation and docking analyses revealed that MUC1 directly interacts with HIF-1α via key residues including PHE1148 and TYR1212, and MUC1 knockdown decreased HIF-1α protein levels in A549 cells. HIF-1α overexpression reversed the protective effects of MUC1 silencing on BLM-induced ER stress, mitochondrial dysfunction, apoptosis, and necroptosis in A549 cells. Consistently, HIF-1α activation abolished the anti-fibrotic benefits of AT2-specific Muc1 deletion in mice, reversing the attenuation of ER stress and mitochondrial dysfunction observed following BLM injury. Furthermore, adeno-associated virus 9 (AAV9)-mediated AT2-specific Muc1 knockdown reversed established lung fibrosis. Collectively, these findings demonstrate that MUC1 promotes pulmonary fibrosis by binding to and stabilizing HIF-1α, which in turn exacerbates ER stress and mitochondrial dysfunction, leading to AT2 cell apoptosis and necroptosis. Therapeutic inhibition of the MUC1-HIF-1α axis in AT2 cells holds great potential as a novel treatment strategy for IPF.

  • Open Access

    Is there a room for radical salvage resection in initially-unresectable non-small cell lung cancer patients after EGFR-TKI based therapy?

    by Feng Su, Hanzhang Chen, Guilin Peng, Jianxing He, Jingpei Li

    Background: Tyrosine kinase inhibitors (TKIs) constitute the standard first-line systemic therapy for patients with unresectable epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Despite their initial efficacy, the majority of patients inevitably develop acquired resistance or experience local recurrence. This study aimed to evaluate the safety and feasibility of minimally invasive radical salvage surgery following TKI-based therapy in a cohort of patients with initially unresectable NSCLC. Methods: This retrospective single-center study evaluated patients who underwent radical salvage lung resection following TKI-based therapy. Surgical safety and short-term efficacy were assessed, and findings were compared with results from previously published studies. Results: Twenty-six patients underwent salvage surgery following first-line treatment with third-generation TKIs; 19 received TKI monotherapy, while seven received a combination of TKIs and chemotherapy. All patients underwent anatomical lung resection, with two cases requiring conversion to open thoracotomy. R0 resection was achieved in 96.2%. An R0 resection was achieved in 96.2% of cases. The median operative time was 145 minutes (range, 105–240 minutes), and the median intraoperative blood loss was 20 mL (range, 10–700 mL). Postoperative complications occurred in four patients (15.4%), including two major events in individuals who had received preoperative TKI therapy for more than 6 months. Compared to those with shorter treatment durations, patients with prolonged preoperative TKI exposure exhibited a longer postoperative hospital stay, although operative time, blood loss, and chest tube duration were comparable. Our perioperative outcomes were consistent with those reported in six prior retrospective studies. Conclusions: Radical salvage lung resection following TKI therapy is a feasible and safe option for carefully selected patients with initially unresectable EGFR-mutant NSCLC. This approach yields high rates of complete (R0) resection with acceptable morbidity. However, patients who have undergone extended preoperative TKI treatment may present with increased technical challenges and warrant meticulous perioperative planning.

  • Top Cited Papers

    Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study

    by Jun Liu, Jingpei Li, Wanli Lin, Di Shao, Lieven Depypere, Zhifeng Zhang, Zhuoyi Li, Fei Cui, Zesen Du, Yuan Zeng, et al.

    Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD‐1 blockade with neoadjuvant therapy. This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. Patients (clinical stage II‐IVA) received two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab‐paclitaxel (260 mg/m2 in total on day 1 and day 8) and cisplatin (75 mg/m2 in total on days 1‐3) of each 21‐day cycle. Surgery was performed approximately 6 weeks after completion of NIC. Primary endpoint was complete pathologic response (CPR) rate in primary tumor. Secondary endpoints were objective response rate (ORR) per RECIST v1.1, 2‐year progression‐free survival (PFS) rate after surgery, PFS, overall survival (OS) and safety during NIC and perioperative period. Between 17 January 2020 and 8 December 2020, 56 patients were enrolled, and 51 received esophagectomy. Data cutoff date was 25 August 2021. The CPR rate was 35.3% (95% CI, 21.7%‐48.9%). NIC had an ORR of 66.7% (95% CI, 40.0%‐70.4%) and treatment‐related adverse events (TRAEs) of low severity (grade 1‐2, 75.0%; grade 3, 10.7%; grade 4‐5, no). No perioperative mortality occurred. Three (5.9%) patients had tumor recurrence and one (2.0%) patient died. The 2‐year PFS rate, median PFS and median OS had not been reached yet. Camrelizumab plus neoadjuvant chemotherapy in resectable ESCC demonstrates promising efficacy with acceptable toxicity, providing a feasible and effective option. Study is ongoing for long‐term survival analyses.


  • Open Access

    A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy

    by Yuan Zeng, Nicholas Mayne, Chi-Fu Jeffrey Yang, Jun Liu, Fei Cui, Jingpei Li, Wenhua Liang, Jianxing He

    Background: Chemotherapy is a common treatment for patients with resected non-small cell lung cancer (NSCLC). However, there are few models for predicting the survival outcomes of these patients. Here, we developed a clinical nomogram for predicting overall survival (OS) in this cohort. Methods: A total of 16,661 patients with resected NSCLC treated with chemotherapy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified prognostic factors and integrated them into a nomogram. The model was subjected to bootstrap internal validation using the SEER database and external validation using a database in China and the National Cancer Database (NCDB). The model’s predictive accuracy and discriminative ability were tested by calibration and concordance index (C-index). Results: Age, sex, number of dissected lymph nodes, extent of surgery, N stage, T stage, and grade were independent factors for OS and were integrated into the model. The calibration curves for probability of 1-, 3-, and 5-year OS showed excellent agreement between the predicted and actual survivals. The C-index of the nomogram was higher than that of the Tumor-Node-Metastasis staging system for predicting OS (training cohort, 0.62 vs. 0.58; China cohort, 0.68 vs. 0.63; NCDB cohort, 0.59 vs. 0.57). Conclusions: We developed a nomogram that can present individual prediction of OS for patients with resected NSCLC who are undergoing chemotherapy. This practical prognostic tool may help clinicians in treatment planning.


  • Open Access

    Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells

    by Jingpei Li, Jun Liu, Weifeng Yue, Ke Xu, Weipeng Cai, Fei Cui, Zhuoyi Li, Wei Wang, Jianxing He

    Andrographolide (Andro), a component from Chinese medicinal herb Andrographis paniculata, could alleviate pulmonary fibrosis in rodents. Yet, whether and how Andro mitigates epithelial‐mesenchymal transition (EMT) induced by TGF‐β1 remain unknown. This study aimed to explore the effect of Andro on TGF‐β1‐induced EMT in human alveolar epithelial cells (AECs) and the mechanisms involved. We illustrated that Andro inhibited TGF‐β1‐induced EMT and EMT‐related transcription factors in alveolar epithelial A549 cells. Andro also reduced TGF‐β1‐induced cell migration and synthesis of pro‐fibrotic factors (ie CCN‐2, TGF‐β1), matrix metalloproteinases (ie MMP‐2, MMP‐9) and extracellular matrix (ECM) components (ie collagen 1), implying the inhibiting effect of Andro on TGF‐β1‐induced EMT‐like cell behaviours. Mechanistically, Andro treatment not only repressed TGF‐β1‐induced Smad2/3 phosphorylation and Smad4 nuclear translocation, but also suppressed TGF‐β1‐induced Erk1/2 phosphorylation and nuclear translocation in A549 cells. And treatment with ALK5 inhibitor (SB431542) or Erk1/2 inhibitors (SCH772984 and PD98059) remarkably reduced EMT evoked by TGF‐β1. In addition, Andro also reduced TGF‐β1‐induced intracellular ROS generation and NOX4 expression, and elevated antioxidant superoxide dismutase 2 (SOD2) expression, demonstrating the inhibiting effect of Andro on TGF‐β1‐induced oxidative stress, which is closely linked to EMT. Furthermore, Andro remarkably attenuated TGF‐β1‐induced down‐regulation of sirtuin1 (Sirt1) and forkhead box O3 (FOXO3), implying that Andro protects AECs from EMT partially by activating Sirt1/FOXO3‐mediated anti‐oxidative stress pathway. In conclusion, Andro represses TGF‐β1‐induced EMT in AECs by suppressing Smad2/3 and Erk1/2 signalling pathways and is also closely linked to the activation of sirt1/FOXO3‐mediated anti‐oxidative stress pathway.


  • Open Access

    A rare collision tumor of squamous carcinoma and small cell carcinoma in esophagus involved with separate lymph nodes: a case report.

    by Jingpei Li, Xiaoke Chen, Yaxing Shen, Yingyong Hou, Shumin Zhang, Hao Wang, Mingxiang Feng, Lijie Tan, Qun Wang, Zhaochong Zeng

    A rare collision tumor of squamous carcinoma and small cell carcinoma in esophagus involved with separate lymph nodes: a case report